Olix Pharmaceuticals Inc., of Suwon, South Korea, said it nominated OLX-10020 as a clinical candidate for geographic atrophy (GA), a severe and advanced form of dry age-related macular degeneration (AMD). OLX-10020 is designed to target an undruggable gene involved in GA, identified by Jayakrishna Ambati, a professor at the University of Virginia, School of Medicine.